跳轉至內容
Merck
  • In vivo architectonic stability of fully de novo designed protein-only nanoparticles.

In vivo architectonic stability of fully de novo designed protein-only nanoparticles.

ACS nano (2014-04-09)
María Virtudes Céspedes, Ugutz Unzueta, Witold Tatkiewicz, Alejandro Sánchez-Chardi, Oscar Conchillo-Solé, Patricia Álamo, Zhikun Xu, Isolda Casanova, José Luis Corchero, Mireia Pesarrodona, Juan Cedano, Xavier Daura, Imma Ratera, Jaume Veciana, Neus Ferrer-Miralles, Esther Vazquez, Antonio Villaverde, Ramón Mangues
摘要

The fully de novo design of protein building blocks for self-assembling as functional nanoparticles is a challenging task in emerging nanomedicines, which urgently demand novel, versatile, and biologically safe vehicles for imaging, drug delivery, and gene therapy. While the use of viruses and virus-like particles is limited by severe constraints, the generation of protein-only nanocarriers is progressively reachable by the engineering of protein-protein interactions, resulting in self-assembling functional building blocks. In particular, end-terminal cationic peptides drive the organization of structurally diverse protein species as regular nanosized oligomers, offering promise in the rational engineering of protein self-assembling. However, the in vivo stability of these constructs, being a critical issue for their medical applicability, needs to be assessed. We have explored here if the cross-molecular contacts between protein monomers, generated by end-terminal cationic peptides and oligohistidine tags, are stable enough for the resulting nanoparticles to overcome biological barriers in assembled form. The analyses of renal clearance and biodistribution of several tagged modular proteins reveal long-term architectonic stability, allowing systemic circulation and tissue targeting in form of nanoparticulate material. This observation fully supports the value of the engineered of protein building blocks addressed to the biofabrication of smart, robust, and multifunctional nanoparticles with medical applicability that mimic structure and functional capabilities of viral capsids.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
咪唑, ReagentPlus®, 99%
Sigma-Aldrich
葡萄糖, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC), BioXtra
Sigma-Aldrich
咪唑, for molecular biology, ≥99% (titration)
Sigma-Aldrich
咪唑水溶液, BioUltra, 1 M in H2O
USP
右旋糖, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
咪唑, ACS reagent, ≥99% (titration)
Sigma-Aldrich
咪唑, BioUltra, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Supelco
D -(+)-葡萄糖, analytical standard
Sigma-Aldrich
D -(+)-葡萄糖, ACS reagent
Supelco
葡萄糖, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D -(+)-葡萄糖, suitable for mouse embryo cell culture, ≥99.5% (GC)
Sigma-Aldrich
咪唑, puriss. p.a., ≥99.5% (GC)
Sigma-Aldrich
咪唑, ≥99% (titration), crystalline
USP
咪唑, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
咪唑, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
D -(+)-葡萄糖, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
D-葡萄糖-12C6, 16O6, 99.9 atom % 16O, 99.9 atom % 12C
Sigma-Aldrich
咪唑, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
Supelco
咪唑, Pharmaceutical Secondary Standard; Certified Reference Material
咪唑, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
D -(+)-葡萄糖, Vetec, reagent grade, ≥99.5% (HPLC)
Sigma-Aldrich
D -(+)-葡萄糖, tested according to Ph. Eur.
昂丹司琼杂质E, European Pharmacopoeia (EP) Reference Standard